• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Chart of the Day, Part 2: A Closer Look at Constellation's Big Cannabis Bet

Canopy Growth's smoking engine won't necessarily ensure smooth sailing for Constellation.
By KEVIN CURRAN Jan 10, 2019 | 01:50 PM EST
Stocks quotes in this article: CGC, STZ, TAP, HYYDF, CRON, MO, NVS, TLRY, HEINY

Canopy Growth (CGC) is being touted as the necessary kick to light up Constellation Brands (STZ) stock, but question marks still loom large for many.

For Thursday's trading, the two are complementing each other to solid gains, with Canopy surging about 10% and Constellation rising about 5%.

However, given the long term nature of the company's forecasts in the space and the remaining roadblocks to growth, the short term risks of the pricey cannabis push cannot be ignored.

"While we do think that valuation can move closer to historical averages over-time, we think uncertainty around Canopy Growth will likely weigh on the multiple for some time," JP Morgan analyst Andrea Teixera commented.

Too Much Too Soon?

Foremost among the concerns is the Canadian cannabis company's eye popping price tag.

The big bet from Constellation is one that pales in comparison to peers and has caused many to question whether the company dove into the deep end too quickly.

"Recently, AB InBev announced a strategic partnership with Tilray to research nonalcohol beverages containing CBD and THC. The partnership is limited to Canada with any decisions regarding commercialization of the beverages to be made in the future," said Guggenheim analyst Laurent Grandet. "This partnership further emphasizes our view that gaining access in the cannabis industry can be done for far cheaper than the $4.2B that Constellation Brands invested in Canopy earlier this year."

The numbers comparison on the two companies carries over to contrasting methods, with many companies forming subsidiaries to do cannabis beverage research or to form joint ventures at lower cost levels.

Most notable were the ventures started by Molson Coors (TAP) alongside Hydropothecary Corp.  (HYYDF) and Heineken's (HEINY) usage of its Lagunitas subsidiary to market a "Hi-Fi Hops" cannabis infused beer.

The only comparable investment is the $1.8 billion by Altria Group (MO) in Cronos Group (CRON) to take a 45% stake in the Canadian cannabis company. Even still, that is a far lower investment than Constellation paid.

Even big pharma companies that are certainly not shy about investing in M&A, are not jumping in with investments nearing Constellation's big bet. Novartis' (NVS) agreement with Tilray (TLRY) , for example, is not causing any known debt drag on the company.

While Constellation has touted its ability to return capital to shareholders even with the impact of its Canopy investment, the short term sting of such a large cash expenditure is still reverberating. 

Further, the increased big name competition is one that could squeeze the entire industry.

Hedge Fund manager Jeffrey Vinik made that point on CNBC on Thursday, arguing that the crowded space offers little opportunity even to big names like Canopy.

"I won't say zero, but my guess is that they're overhyped," Vinik said. "There's going to be too much competition, margins are going to come down, [and] nobody's going to make money."

Bottom Line

The potential growth engine that cannabis presents as the recreational market looks ready to open up could be worth hundreds of billions of dollars. Canopy Growth, as one of the best run and most well-funded companies in the space, would be a key company to target in the space.

Still, one should not take the catalysts alone and ignore the unanswered questions as they relate to Constellation Brands' specific investment and the volatile nature of the cannabis market.

Canopy could be the key to differentiating Constellation from its peers and vindicate CEO Rob Sand's bet. But given the developing nature of the cannabis industry, investors will need to exercise some patience before they find out whether or not returns can grow like  weed.

Read Part 1 of this article, here.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | Stocks | Food & Drink | Canada | Cannabis | Stock of the Day

More from Stocks

Shares of Xencor Could Be Bought on a 50% Correction

Bruce Kamich
Jul 1, 2022 11:59 AM EDT

Traders should remain patient.

Let's Size Up the Market's Prospects for the Second Half of 2022

Bret Jensen
Jul 1, 2022 11:30 AM EDT

The next six months can't be worse than the first six, can they?

In an Ugly First Half for Stocks, Value Was a Lot Less Ugly Than Growth

Jonathan Heller
Jul 1, 2022 11:00 AM EDT

A look at the Russell indexes shows that value stocks suffered in the first six months of 2022 but not nearly as much as growth issues.

Nuvalent Has Begun the Bottoming Process

Bruce Kamich
Jul 1, 2022 10:52 AM EDT

Let's check the charts and indicators.

You Can Invest in Micron, But Here's Why You May Want to Wait

Stephen Guilfoyle
Jul 1, 2022 10:15 AM EDT

MU reported earnings Thursday night and the guidance was shocking.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 07:59 PM EDT PAUL PRICE

    Very good quarterly numbers from Bassett Furniture (BSET)

    Bassett Furniture (BSET) blew right through analys...
  • 04:41 PM EDT PAUL PRICE

    First Half Results - Putrid Second Half Results - Likely to Be Much Better

    It's great that we're done with June. 2022 marked...
  • 04:51 PM EDT PAUL PRICE

    We Should Be in for Better Starting Soon

    Window dressing Thursday, the last day of the...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login